Jan W. Eriksson - Concepedia

Author

Jan W. Eriksson

Also Known As

Bengt-Olov Tengmark, Eriksson, Jan, Eriksson, Jan W, Eriksson, Jan W., J Eriksson, J W Eriksson, J. Bolinder, J. ERIKSSON, J. Eriksson, J. W. ERIKSSON

386

Publications

13.6K

Citations

H-Index

151

Concepts

All Affiliations

Uppsala University Umeå University AstraZeneca (Sweden)Sahlgrenska University Hospital University of Gothenburg

About

Jan W. Eriksson is an author at Uppsala University specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	64	4.3K
2	Health Sciences	27	38	2.1K
3	Public Health	6	6	1.1K
4	Natural Sciences	5	5	358
5	Engineering	3	3	169

Jan W. Eriksson

193

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes Bo Åhrén, Erik Simonsson, Hillevi Larsson, Diabetes Care	2002	423
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson, Diabetologia	2018	368
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementDiabetes EpidemiologyCardiovascular EpidemiologyHealth Policy	2017	363
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, The Lancet Diabetes & Endocrinology Diabetes ManagementUrologyMedicineDiabetesChronic Kidney Disease	2019	317
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial Paresh Dandona, Chantal Mathieu, Moshe Phillip, The Lancet Diabetes & Endocrinology Metabolic SyndromeType 1Diabetes ManagementHealth PolicyCardiovascular Disease	2017	286
Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS) Bengt Littorin, Puck J.J. Blom, Anna Schölin, Diabetologia Young AdultsDiabetes EpidemiologyDiabetesControl SubjectsDiabetes Mellitus	2006	276
Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’ Maria Lundgren, Maria Svensson, Stina Lindmark, Diabetologia ObesityMetabolic SyndromeInsulin ResistanceMetabolic DisorderMedicine	2007	269
The risk of venous thromboembolism is markedly elevated in patients with diabetes Vaida Petrauskienė, Markus Falk, Ingeborg Waernbaum, Diabetologia Metabolic SyndromeThrombosisDiabetes ManagementDiabetes EpidemiologyVenous Disease	2005	216
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( <scp>CVD‐REAL Nordic</scp> ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: <scp>A</scp> multinational observational study Frederik Persson, Thomas Nyström, Marit E. Jørgensen, Diabetes Obesity and Metabolism	2017	214
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study Kåre I. Birkeland, Johan Bodegård, Jan W. Eriksson, Diabetes Obesity and Metabolism	2020	211

Page 1